금융 뉴스 허브

Trinity expects $2.20 to $2.40 full-year EPS while projecting Rail Products margin at the low end of 5% to 6%

U.S. dollar sees biggest two-day drop since Liberation Day

Jersey Mike’s Prices Below What Blackstone Paid For It

Ten times oversubscribed, the biggest consumer listing of the year, and still a discount to what a hungry Steve Schwarzman paid in 2024

Lexaria Announces Effective Date for Reverse Stock Split

KELOWNA, BC / ACCESS Newswire / July 30, 2026 / Lexaria Bioscience Corp. (Nasdaq:LEXX) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, announces that it intends to effect ...

Intel Stock's Biggest Risk Is A Foundry Bill Due Long Before The Customers

Demand is not Intel's problem; what a holder is really underwriting is years of capital spending that must be paid long before the foundry meant to justify it can prove itself.

LKQ sinks on weak Q2 results and cuts full-year guidance

Missiles Are Hot. That’s Good for Lockheed Martin Stock.

The U.S. has fired a lot of missiles lately, leaving the Defense Department motivated to quickly replace and grow its missile stocks. “When you add the $54 billion dollars in this contract modificati ...

Meta’s stock is falling hard. Here’s why the company is in Wall Street’s doghouse.

Meta’s spending on AI is ramping, and investors want proof that the company can make serious money in areas other than advertising.

VHT vs. PBE: Which Health Care ETF Is the Better Buy?

PBE delivered the better return over the past year, but has experienced greater historical volatility. VHT's more diversified portfolio and rock-bottom fees offer investors a steadier, lower-cost opti ...

Pioneering AI hedge fund with returns of 1000% since inception discovers the downside of leverage

AI wunderkind Leopold Aschenbrenner has reportedly asked investors for an injection of fresh capital, and offered them to opportunity to buy some of its assets directly from the fund.

Bristol Myers Raises Earnings Guidance, Stock Falls

Bristol Myers Squibb faces declining revenue in its legacy drug portfolio, but new products like Opdivo are offsetting the drop.

California Water Service GAAP EPS of $0.93 misses by $0.14, revenue of $308.6M misses by $28.8M